Cases & Deals

  • Home
  • Practices
  • Sumitomo completes sale of $648 million of Common Shares of Roivant Sciences Ltd.

Share

Sumitomo completes sale of $648 million of Common Shares of Roivant Sciences Ltd.

April 2024

Client(s) Sumitomo Pharma Co., Ltd.

Jones Day represented Sumitomo Pharma Co., Ltd. in connection with its privately negotiated sale of $648 million of Common Shares of Roivant Sciences Ltd.

Contacts

Before sending, please note:

Information on www.jonesday.com is for general use and is not legal advice. The mailing of this email is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Anything that you send to anyone at our Firm will not be confidential or privileged unless we have agreed to represent you. If you send this email, you confirm that you have read and understand this notice.